Lung Cancer

The use of a multi-agent chemotherapy regimen resulted in improved outcomes in a group of children with pleuropulmonary blastoma, a rare form of lung cancer, when compared with other regimens.

A breast cancer research nurse and lung cancer survivor stresses the importance of participating in clinical trials that are investigating the latest treatments.

Treatment with an investigational drug elicited a median progression-free survival (time from treatment until disease progression or death) of 8.9 months among patients with a form of unresectable or metastatic squamous non-small cell lung cancer, according to trial findings.

Lung cancer advocates and clinicians must ”fight” for every patient with the disease and ensure that the most amount of people can benefit from advancements in the field, according to an advocate.

Dr. Pierre de Delva works tirelessly to bring better outcomes to patients with lung cancer who live in Mississippi — a state that traditionally has poor lung cancer outcomes.

After being diagnosed with late-stage cancer, I learned many lessons, including the fact that I had to be my own best advocate.

The FDA’s approval of Vegzelma was based on data that demonstrated the biosimilar elicited comparable safety and efficacy to Avastin in several studies.

The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.

CURE®’s Lung Cancer Heroes® Award Program honors and gives thanks to those heroes who have positively affected the lives of patients with lung cancer.

The Food and Drug Administration approved Retevmo for the treatment of patients with advanced or metastatic non-small cell lung cancer with a rearranged RET gene fusion.

Three out of four women with lung cancer reported experiencing moderate to severe sexual dysfunction, a survey shows.

Lumakras outperformed chemotherapy in reducing the risk of progression or death and improving quality of life for patients with KRAS G12C-mutated non-small cell lung cancer, study results showed.

An expert discusses what patients need to know about the recent FDA approval of Enhertu for HER2-mutant non-small cell lung cancer, an aggressive subtype of the disease.

When going through treatment for advanced-stage lung cancer, people would often talk to me like I was a child, or ignore me altogether and speak to my husband.

The first patient has been treated with H002, a novel drug being investigated for non-small cell lung cancer that is resistant to a prior EGFR TKI treatment.

More patients with pretreated non-small cell lung cancer saw their disease disappear with abivertinib compared to Tagrisso.

When doctors told me that there was no more they could do for my stage 4 lung cancer, I refused to believe them, and wish other patients did the same.

The FDA’s approval of Enhertu marks the first approval of a drug for patients with HER2-mutant unresectable or metastatic non-small cell lung cancer.

The FDA approved Tabrecta for patients with non-small cell lung cancer who have a mutation that led to MET exon 14 skipping.

Imfinzi plus tremelimumab led to better overall survival outcomes compared to standard chemotherapy in patients with metastatic non-small cell lung cancer.

According to real-world data, EGFR C797X mutation is deemed the leading resistance mechanism to treatment with Tagrisso in patients with non-small cell lung cancer.

Sugemalimab demonstrated safe and efficacious results when given after concurrent chemoradiation therapy or short-course chemoradiation therapy for patients with lung cancer.

Treatment with Onivyde failed to best the chemotherapy topotecan in improving overall survival in patients with small cell lung cancer whose disease failed to respond to platinum-based first-line treatment, according to findings from a primary analysis of the phase 3 RESILIENT trial.

Subcutaneous (injectable) Tecentriq had similar movement throughout the body, while saving on treatment time compared to intravenous administration of the drug in a group of patients with non-small cell lung cancer.

In honor of World Lung Cancer Day, CURE® compiled the five most-read lung cancer-related news items from 2022 that patients may have missed.

Watch Dr. Ravi Salgia, Dr. Erminia Massarelli, Dr. Jyoti Malhotra and Daniel Saez answer questions about advancements in lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Jyoti Malhotra, from City of Hope, discuss advancements in advanced-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Erminia Massarelli, from City of Hope, discuss advancements in early-stage non-small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Dr. Ravi Salgia, from City of Hope, discuss advancements in small cell lung cancer during the CURE Educated Patient Lung Cancer Summit.

Watch Nikki Martin, Dr. Ying-Chun Lo and Dr. Hossein Borghaei discuss overcoming barriers to receiving biomarker testing during the CURE Educated Patient Lung Cancer Summit.